Tissue Regeneration Technologies: 251 Heritage Walk Woodstock, GA 30188|(404) 402-6844
Woodstock, GA, April 19, 2016 – Tissue Regeneration Technologies, LLC (TRT) announces an Exclusive License Agreement with Acoustic Wave Cell Therapy, Inc. (AWCT), a Delaware Corporation, whereby AWCT will utilize TRT's extensive patent portfolio to develop and market low energy acoustic wave treatments for multiple internal organs and associated tissues and pathologies.
AWCT’s founder and Chief Medical Officer is Dr. Tom Lue, a renowned researcher and clinician, and Professor of Urology at the University of California San Francisco (UCSF) for over 30 years. UCSF is home to one of the world's premier medical centers and is the leading public recipient of biomedical research grants from the National Institutes of Health. Five of its researchers have received the Nobel Prize in Medicine and Physiology. Dr. Lue and his research team have spent the last five years working with TRT technology at UCSF to develop optimized protocols to treat different tissue types and organs in preclinical studies. In their UCSF research laboratory, they have successfully regenerated damaged tissues in various organs in animals and established the safety of their protocols.
AWCT has obtained from UCSF an exclusive license to the patent rights associated with Dr. Lue’s discoveries. AWCT will now take over the clinical development and do all work necessary to obtain FDA approval for these treatments. Therapeutic targets include diseases of the liver, kidney, urinary tract and pancreas.
Charles Engles, AWCT’s CEO stated: “TRT has been a visionary in recognizing the vast therapeutic potential of low energy acoustic waves and has assembled the largest patent portfolio in the industry. We are pleased to be able to work with TRT to commercialize this technology and make low energy acoustic wave therapy the standard of care for the treatment of specific internal organ disorders.”